Jakavi 15 Mg Tablet 14
Description
Jakavi tablet It is used to treat myelofibrosis and polycythemia vera (a type of blood cancer where the body produces too many red blood cells) in individuals who are resistant to or cannot be successfully treated with hydroxyurea. It is indicated for the treatment of acute graft-versus-host disease (a complication of the transplant procedure that replaces diseased bone marrow with healthy bone marrow) previously treated unsuccessfully with steroid medications in adults and children aged 12 and older.
Common side effects of this medication include headache, dizziness, and a low platelet count. It may also decrease the number of red blood cells in your blood, which can increase your susceptibility to infections. Regular blood tests are necessary to monitor your blood cell levels, along with your heart, liver, kidney, and lipid levels.
Before starting this medication, inform your doctor if you have liver or kidney issues, or if you are taking any medications for infections. Many other medications can interact with this treatment, so it is important to inform your healthcare team about all the medications you are currently using.
This medicine is not recommended during pregnancy or while breastfeeding. Both males and females should use effective contraception during treatment to avoid the risk of pregnancy.
Product Summary
| Offer Price | ₹49761.91 |
| You Save | ₹6785.71 (12% on MRP) |
| Contains | Ruxolitinib(15.0 Mg) |
| Uses | Blood cancers like myelofibrosis and polycythemia vera |
| Side effects | Urinary tract infections, dizziness and headache |
| Therapy | ANTI-NEOPLASTIC |
Uses
- Myelofibrosis includes primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis.
- Polycythemia vera patients who resist or cannot tolerate hydroxyurea, especially when myelofibrosis or polycythemia vera does not respond to it, require alternative treatments.
- Acute graft-versus-host disease, a complication of the transplant procedure that replaces diseased bone marrow with healthy bone marrow, has been previously treated unsuccessfully with steroid medications in adults and children aged 12 and older....
Contraindications
- Allergy to Ruxolitinib or any excipients of Jakavi tablet.
- Pregnancy and lactation.
Side effects
- Infections:
- Urinary tract infections
- Herpes zoster
- CMV infections (cytomegalovirus)
- Sepsis
- Blood and Lymphatic System Disorders:
- Anaemia (low red blood cell count)
- Thrombocytopenia (low platelet count)
- Neutropenia (low neutrophil count)
- Bleeding (including various types such as bruising, gastrointestinal, intracranial, nosebleeds, post-procedural, and blood in urine)
- Bruising
- Metabolism and Nutrition Disorders:
- Hypercholesterolaemia (high cholesterol)
- Hypertriglyceridaemia (high triglycerides)
- Weight gain
- Nervous System Disorders:
- Dizziness
- Headache
- Gastrointestinal Disorders:
- Elevated lipase (an enzyme)
- Constipation
- Nausea
- Increased amylase (an enzyme)
- Hepatobiliary Disorders (liver & bile ducts):
- Increased alanine aminotransferase (ALT)
- Increased aspartate aminotransferase (AST)
- Vascular Disorders:
- Hypertension (high blood pressure)
- Musculoskeletal and Connective Tissue Disorders:
- Increased blood creatine phosphokinase (CPK)
- Renal and Urinary Disorders:
- Increased blood creatinine
Precautions and Warnings
Other General Warnings
- You have a lower platelet count.
- You develop signs or symptoms of an infection.
- You have an active serious infection.
- You have a history of tuberculosis or have been in close contact with someone who has tuberculosis.
- You have chronic Hepatitis B infection (as your doctor may need to monitor your HBV viral load).
- You notice early signs and symptoms of herpes zoster (shingles).
- You experience any new or worsening cognitive, neurological, or psychiatric symptoms or signs (as these could be suggestive of Progressive Multifocal Leukoencephalopathy (PML)).
- You have lipid abnormalities (high cholesterol or triglycerides).
- You are 65 years of age or older.
- You are a current or past long- time smoker.
- You have a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.
- You have cardiovascular risk factors.
- You have additional risk factors for venous thromboembolic events (VTE), such as a history of VTE, major surgery, immobilization, combined hormonal contraceptives or hormone replacement therapy, or an inherited coagulation disorder....
- You develop symptoms of thrombosis (such as leg swelling, pain, redness, or chest pain and shortness of breath).
- You have a history of extended treatment with hydroxyurea or prior non- melanoma skin cancer (NMSC) or pre- malignant skin lesions (as periodic skin examination is recommended).
- You have severe kidney impairment or are on haemodialysis (as your starting dose of Jakavi may need to be reduced).
- You have liver impairment.
- You experience a return of myelofibrosis (MF) symptoms after stopping or interrupting Jakavi.
Directions for Use
Storage and disposal
Dosage
Missed a Dose
Overdose
Mode of Action
How Does It Work?
Interactions
Interactions with other medicines
Content Details
Ravindra Ghongade
B. Pharm
Dr. Nikita Toshi
BDS (Bachelor of Dental Surgery), WHO FIDES member
Did you find this medicine information helpful?
Please rate your experience
Blog Articles
Chronic Condition Articles
Top-Tests we cover:
Top-Selling Healthcare Products:
Top-Selling Medicines:
Top-Searched Medicines:
